News and Announcements
Novogen, The Future of Cancer Therapy, Releases Jun 2017 Newsletter
- Published June 07, 2017 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Novogen (ASX: NRT) is an Australian oncology-focused biotechnology company that is pleased to present the company’s June 2017 Newsletter.
KEY TAKEAWAYS:
- In April, Novogen planned phase II clinical trial in relation to the most common and aggressive form of primary brain cancer. Novogen plans to focus the study on the almost two-thirds of patients.
- Approximately 200 patients will be recruited, and the company aims to start the study in the second half of calendar 2017.
- The study will be a randomised controlled trial and, if it is successful, it may offer an opportunity to approach FDA, the US regulatory agency, to discuss accelerated approval without waiting for a full phase III study.
- Phase I study of Cantrixil in ovarian cancer is progressing well. Five of the six participating hospitals are now open to recruitment. The timing of initial data is difficult to predict, because the design entails increasing doses until patients start to experience side effects, and this cannot be accurately predicted in advance.
- Novogen’s decision during April to terminate the development of Anisina, the lead program from the company’s anti-tropomyosin research. Despite the great work that has been done with Anisina, the emerging data did not, in our view, make it a promising candidate to take forward into human trials.
- In closing, the Novogen team remains tightly focused on delivering its programs.
Company Updates
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
The Light Fantastic: Why Invion’s Photodynamic Therapy May Be Attracting Big Pharma’s Attention
Invion Limited is challenging the status quo in oncology with its Photosoft™ platform, a precision therapy that uses light-activated molecules to selectively target cancer cells. By transforming the body’s own immune response and addressing the high costs of current cancer treatments, Invion is positioning itself as a transformative player in the biotech sector. With clinical trials underway and strong institutional partnerships, the company is bridging the gap between scientific breakthrough and accessible, scalable patient care.
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship
From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.
Backed By Leading Investment Groups and Family Offices
